Abbott Laboratories (ABT.N)
23 May 2018
Thu, May 3 2018
* ABBOTT EXPANDS CARDIAC ARRHYTHMIAS PORTFOLIO WITH FDA CLEARANCE OF ADVANCED MAPPING CATHETER
* ABBOTT'S XIENCE SIERRA™ HEART STENT RECEIVES NATIONAL REIMBURSEMENT IN JAPAN TO TREAT PEOPLE WITH CORONARY ARTERY DISEASE Source text for Eikon: Further company coverage:
BRIEF-Abbott Laboratories Says Shareholders Rejected Proposal Requesting Board Of Directors Adopt Policy That Board Chairman Be Independent Director
* ABBOTT LABORATORIES SAYS SHAREHOLDERS REJECTED PROPOSAL REQUESTING CO'S BOARD OF DIRECTORS ADOPT POLICY THAT BOARD CHAIRMAN BE INDEPENDENT DIRECTOR Source text: (https://bit.ly/2KqCwQY) Further company coverage:
BRIEF-Abbott Laboratories - Co, Sanquin Sign Multiple-Year Contract For Supply Of Primary Serological Equipment And Consumables
* ABBOTT LABORATORIES - CO, SANQUIN SIGN MULTIPLE-YEAR CONTRACT FOR SUPPLY OF PRIMARY SEROLOGICAL EQUIPMENT AND CONSUMABLES Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
Abbott Laboratories' just beat expectations for first quarter profits and revenue on Wednesday but stuck to a full-year profit forecast some investors had expected would be raised, sending the healthcare company's shares lower.
* Analysts cite disappointment on whisper numbers among investors
* Q1 GAAP EARNINGS PER SHARE $0.23 FROM CONTINUING OPERATIONS
April 18 Abbott Laboratories on Wednesday posted a 16.7 percent rise in quarterly revenue, helped by strong demand for its newer devices.
BRIEF-Abbott Initiates Groundbreaking Study To Assess Superiority Of High-Resolution Imaging Versus Standard-Of Care Angiography In Treating Coronary Artery Disease
* RESOLUTION IMAGING RESULT IN LARGER VESSEL DIAMETERS Source text for Eikon: Further company coverage:
* ABBOTT INITIATES TRIAL TO EVALUATE IMPROVED SURVIVAL AND OUTCOMES WITH THE CARDIOMEMS MONITOR